Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.

Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, Brock W, De la Cruz Cabrera O, Guda K, Barnholtz-Sloan JS, Iyer PG, Canto MI, Wang JS, Shaheen NJ, Thota PN, Willis JE, Chak A, Markowitz SD.

Sci Transl Med. 2018 Jan 17;10(424). pii: eaao5848. doi: 10.1126/scitranslmed.aao5848.


Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin.

Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, LaFramboise T, Mazard T, Feng T, Hamilton S, Broom B, Lutterbaugh J, Issa JP, Markowitz SD, Kopetz S.

Oncotarget. 2016 Oct 11;7(41):67495-67506. doi: 10.18632/oncotarget.11317.


Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer.

Venkitachalam S, Revoredo L, Varadan V, Fecteau RE, Ravi L, Lutterbaugh J, Markowitz SD, Willis JE, Gerken TA, Guda K.

Sci Rep. 2016 Mar 23;6:23642. doi: 10.1038/srep23642.


ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients.

Varadan V, Singh S, Nosrati A, Ravi L, Lutterbaugh J, Barnholtz-Sloan JS, Markowitz SD, Willis JE, Guda K.

Genome Med. 2015 Jul 20;7:69. doi: 10.1186/s13073-015-0192-9. eCollection 2015.


Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):E2853. doi: 10.1073/pnas.1505059112. Epub 2015 May 4. No abstract available.


Novel recurrently mutated genes in African American colon cancers.

Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, Beard L, Willson JK, Sedwick WD, Wang ZJ, Molyneaux N, Miron A, Adams MD, Elston RC, Markowitz SD, Willis JE.

Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1149-54. doi: 10.1073/pnas.1417064112. Epub 2015 Jan 12.


Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer.

Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, Wang J, Willis JE, Makar KW, Ulrich CM, Lutterbaugh JD, Shrubsole MJ, Zheng W, Markowitz SD, Grady WM.

Gastroenterology. 2014 Aug;147(2):418-29.e8. doi: 10.1053/j.gastro.2014.04.039. Epub 2014 Apr 30.


GNAS mutations identify a set of right-sided, RAS mutant, villous colon cancers.

Fecteau RE, Lutterbaugh J, Markowitz SD, Willis J, Guda K.

PLoS One. 2014 Jan 30;9(1):e87966. doi: 10.1371/journal.pone.0087966. eCollection 2014.


NTRK3 is a potential tumor suppressor gene commonly inactivated by epigenetic mechanisms in colorectal cancer.

Luo Y, Kaz AM, Kanngurn S, Welsch P, Morris SM, Wang J, Lutterbaugh JD, Markowitz SD, Grady WM.

PLoS Genet. 2013;9(7):e1003552. doi: 10.1371/journal.pgen.1003552. Epub 2013 Jul 11.


Genetic variation in 15-hydroxyprostaglandin dehydrogenase and colon cancer susceptibility.

Thompson CL, Fink SP, Lutterbaugh JD, Elston RC, Veigl ML, Markowitz SD, Li L.

PLoS One. 2013 May 22;8(5):e64122. doi: 10.1371/journal.pone.0064122. Print 2013.


H3K4me3 inversely correlates with DNA methylation at a large class of non-CpG-island-containing start sites.

Balasubramanian D, Akhtar-Zaidi B, Song L, Bartels CF, Veigl M, Beard L, Myeroff L, Guda K, Lutterbaugh J, Willis J, Crawford GE, Markowitz SD, Scacheri PC.

Genome Med. 2012 May 28;4(5):47. doi: 10.1186/gm346.


Epigenomic enhancer profiling defines a signature of colon cancer.

Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF, Willis J, Moore JH, Tesar PJ, Laframboise T, Markowitz S, Lupien M, Scacheri PC.

Science. 2012 May 11;336(6082):736-9. doi: 10.1126/science.1217277. Epub 2012 Apr 12.


Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies.

Moinova H, Leidner RS, Ravi L, Lutterbaugh J, Barnholtz-Sloan JS, Chen Y, Chak A, Markowitz SD, Willis JE.

Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):594-600. doi: 10.1158/1055-9965.EPI-11-1060. Epub 2012 Feb 7.


Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers.

Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, Lowe JB, Wiesner GL, Parmigiani G, Barnholtz-Sloan J, Dawson DW, Velculescu VE, Kinzler KW, Papadopoulos N, Vogelstein B, Willis J, Gerken TA, Markowitz SD.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12921-5. doi: 10.1073/pnas.0901454106. Epub 2009 Jul 17.


Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.

Guda K, Natale L, Lutterbaugh J, Wiesner GL, Lewis S, Tanner SM, Tomsic J, Valle L, de la Chapelle A, Elston RC, Willis J, Markowitz SD.

Cancer Res. 2009 Jun 15;69(12):4959-61. doi: 10.1158/0008-5472.CAN-09-0225. Epub 2009 Jun 9.


15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.

Yan M, Myung SJ, Fink SP, Lawrence E, Lutterbaugh J, Yang P, Zhou X, Liu D, Rerko RM, Willis J, Dawson D, Tai HH, Barnholtz-Sloan JS, Newman RA, Bertagnolli MM, Markowitz SD.

Proc Natl Acad Sci U S A. 2009 Jun 9;106(23):9409-13. doi: 10.1073/pnas.0902367106. Epub 2009 May 22.


Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene.

Chen WD, Han ZJ, Skoletsky J, Olson J, Sah J, Myeroff L, Platzer P, Lu S, Dawson D, Willis J, Pretlow TP, Lutterbaugh J, Kasturi L, Willson JK, Rao JS, Shuber A, Markowitz SD.

J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32.


15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers.

Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK, Luo G, Hensold J, Tai HH, Wilson K, Markowitz SD.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17468-73. Epub 2004 Dec 1.


A subset of familial colorectal neoplasia kindreds linked to chromosome 9q22.2-31.2.

Wiesner GL, Daley D, Lewis S, Ticknor C, Platzer P, Lutterbaugh J, MacMillen M, Baliner B, Willis J, Elston RC, Markowitz SD.

Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12961-5. Epub 2003 Oct 17.


SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers.

Li H, Myeroff L, Smiraglia D, Romero MF, Pretlow TP, Kasturi L, Lutterbaugh J, Rerko RM, Casey G, Issa JP, Willis J, Willson JK, Plass C, Markowitz SD.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8412-7. Epub 2003 Jun 26.


PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer.

Brunschwig EB, Wilson K, Mack D, Dawson D, Lawrence E, Willson JK, Lu S, Nosrati A, Rerko RM, Swinler S, Beard L, Lutterbaugh JD, Willis J, Platzer P, Markowitz S.

Cancer Res. 2003 Apr 1;63(7):1568-75.


Silence of chromosomal amplifications in colon cancer.

Platzer P, Upender MB, Wilson K, Willis J, Lutterbaugh J, Nosrati A, Willson JK, Mack D, Ried T, Markowitz S.

Cancer Res. 2002 Feb 15;62(4):1134-8.


Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer.

Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD.

Cancer Res. 2001 Feb 1;61(3):900-2.


Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line.

Fink SP, Swinler SE, Lutterbaugh JD, Massagué J, Thiagalingam S, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 2001 Jan 1;61(1):256-60.


Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability.

Ma AH, Xia L, Littman SJ, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L, Lutterbaugh J, Modrich P, Veigl ML, Markowitz SD, Sedwick WD.

Oncogene. 2000 Apr 27;19(18):2249-56.


Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers.

Grady WM, Myeroff LL, Swinler SE, Rajput A, Thiagalingam S, Lutterbaugh JD, Neumann A, Brattain MG, Chang J, Kim SJ, Kinzler KW, Vogelstein B, Willson JK, Markowitz S.

Cancer Res. 1999 Jan 15;59(2):320-4.


Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers.

Veigl ML, Kasturi L, Olechnowicz J, Ma AH, Lutterbaugh JD, Periyasamy S, Li GM, Drummond J, Modrich PL, Sedwick WD, Markowitz SD.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8698-702.


Increased transversions in a novel mutator colon cancer cell line.

Eshleman JR, Donover PS, Littman SJ, Swinler SE, Li GM, Lutterbaugh JD, Willson JK, Modrich P, Sedwick WD, Markowitz SD, Veigl ML.

Oncogene. 1998 Mar 5;16(9):1125-30.


Spontaneous apoptosis in human colon tumor cell lines and the relation of wt p53 to apoptosis.

Wang C, Eshleman J, Lutterbaugh J, Bin Y, Willson J, Markowitz S.

Chin Med J (Engl). 1996 Jul;109(7):537-41.


Diverse hypermutability of multiple expressed sequence motifs present in a cancer with microsatellite instability.

Eshleman JR, Markowitz SD, Donover PS, Lang EZ, Lutterbaugh JD, Li GM, Longley M, Modrich P, Veigl ML, Sedwick WD.

Oncogene. 1996 Apr 4;12(7):1425-32.


A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability.

Myeroff LL, Parsons R, Kim SJ, Hedrick L, Cho KR, Orth K, Mathis M, Kinzler KW, Lutterbaugh J, Park K, et al.

Cancer Res. 1995 Dec 1;55(23):5545-7.


Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.

Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, et al.

Science. 1995 Jun 2;268(5215):1336-8.


Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival

Markowitz S, Hines JD, Lutterbaugh J, Myeroff L, Mackay W, Gordon N, Rustum Y, Luna E, Kleinerman J.

Clin Cancer Res. 1995 Apr;1(4):441-5.


Supplemental Content

Loading ...
Support Center